Stay updated on Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.

Latest updates to the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedAdded Revision: v3.6.5 and removed Revision: v3.6.4, indicating the page now reflects a newer document version. This is a small versioning update rather than a substantive change to the study details.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, indicating a new version of the page. There are no visible updates to the study details or associated information.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page's revision tag changed from v3.6.0 to v3.6.3, representing an update to the page's versioning metadata rather than a change to study details.SummaryDifference0.1%

- Check75 days agoChange DetectedEnrollment status now shows 'No longer looking for participants,' indicating that recruitment for this study has ended. The page also adds new help/navigation items ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') and updates the revision label to v3.6.0, while removing the older 'Intervention / Treatment' header variant.SummaryDifference0.4%

- Check82 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5 on the page, signaling a minor version update rather than changes to the study details.SummaryDifference0.1%

- Check103 days agoChange DetectedThe page footer shows Revision: v3.5.4, replacing Revision: v3.5.3. This indicates a small update to the page's versioning/documentation rather than a change to the study content.SummaryDifference0.1%

Stay in the know with updates to Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.